MDSpire - Summary
From the Journals

Can Shorter TB Prevention Regimens Work?

Randomized study evaluates efficacy, safety, and completion in high-risk patients

Share

A study led by Lifan Zhang, MD, from the Chinese Academy of Medical Sciences, investigates the efficacy of a modified 3-month regimen of rifapentine and isoniazid compared to the standard 9-month isoniazid treatment in preventing tuberculosis (TB) among patients with rheumatic diseases and latent TB infection. Conducted with 536 participants, findings indicate that the shorter regimen has a similar safety profile and treatment completion rate while demonstrating a notable reduction in TB cases. The trial, highlighted in eClinicalMedicine, points toward a promising alternative treatment that could alleviate the burden of TB prevention in susceptible populations.

Original Source(s)

Can Shorter TB Prevention Regimens Work?

  • by Julia Cipriano, MS, CMPP

  • March 23, 2026

Related Content

Lyme Vaccine Advances in Late Trial

Large global study evaluates novel prevention strategy.

Why Copilots Failed in R&D and What Comes Next 

Organizations that benefit most from AI in R&D will be those that align technology with scientific reality

RSV Vaccine Eligibility Expands

Trial data show noninferior immune response in high-risk adults aged 18 to 49 years.